Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC

This study uses advanced genetic and molecular testing (multi-omics) on tumor tissue and blood samples to predict how well patients with recurrent or metastatic nasopharyngeal carcinoma (a cancer of the upper throat behind the nose) will respond to immunotherapy treatments. **You may be eligible if...** - You have recurrent or metastatic nasopharyngeal carcinoma - You are 18–70 years old (any gender) - You are well enough to perform daily activities (ECOG 0–1) - You have signed informed consent **You may NOT be eligible if...** - You have or have had another cancer - You are currently enrolled in another clinical trial - You have a drug or alcohol dependency - You have a mental disorder affecting your ability to consent - You are pregnant or breastfeeding - You have uncontrolled high blood pressure or severe complications Talk to your doctor to see if this trial is right for you.